source
- Tango to launch Phase 3 trial in pancreatic cancer after promising combo resultsTango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting, where…
- Roche to pay $700M upfront to Nurix for BTK degrader collaboration, deal up to $2.3BRoche announced a collaboration with Nurix Therapeutics to develop a BTK degrader for B cell malignancies. Roche will provide $700 million upfront, and the agreement could be worth up to $2.3 bill…